Curis, Inc. Message Board
- Reply to
"Celldex has only begun to scratch the surface" That is why you want to buy.
by weightbayou •Jun 10, 2013 9:15 PMAnd could complement inhibitors have a role in fighting Alzheimers.
Int J Alzheimers Dis. 2012;2012:983640. doi: 10.1155/2012/983640. Epub 2012 Aug 21. Microglia, Alzheimer's disease, ... and disrupt complement inhibitor production. -
And Astex is in the middle of this exciting market with their partnered drug AZD3293.
A Two-part Multiple Dose Study to Assess the Safety and Effects of AZD3293 in Healthy Elderly and Alzheimer's Patients
This study is currently recruiting participants.
Verified March 2013 by AstraZeneca
Sponsor:
AstraZeneca
Information provided by (Responsible Party):
AstraZenecaClinicalTrials.gov Identifier:
NCT01795339
First received: February 18, 2013
Last updated: March 22, 2013
Last verified: March 2013Sentiment: Strong Buy
-
From MF
Celldex' promise isn't limited to cancer vaccines. The proprietary APC targeting platform provides an abundance of possible treatment courses, and Celldex has only begun to scratch the surface. Antibodies targeted to APCs can also be conjugated to immunomodulators for immunosuppression in allergic reaction, inflammation, organ transplant, or autoimmune disorders (including an HIV vaccine in Phase 1 trials). Celldex also obtained rights from Amgen for a potent immunostimulant, now called CDX-301.
Bottom line
With a $114 million capital raise and $16 million cash burn in the first quarter, Celldex has plenty of fuel to carry it through rindopepimut and CDX-011 trials and continue preclinical investigation of other immunotherapy applications. I also anticipate some pretty lucrative partnerships, as Celldex is openly shopping for commercialization and R&D partners.Sentiment: Strong Buy
-
Get on the cldx train.
-
The list is back.
Sentiment: Strong Buy
-
-
That is odd.
- Reply to
Important!! This trial uses a vaccine similar to CDX-1401
by weightbayou •Jun 10, 2013 5:00 PMCDX-1401 is a fusion protein consisting of a fully human monoclonal antibody with specificity for the dendritic cell receptor, DEC-205, linked to the NY-ESO-1 tumor ...
-
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
This study is currently recruiting participants.
Verified March 2013 by Roswell Park Cancer Institute
Sponsor:
Roswell Park Cancer Institute
Information provided by (Responsible Party):
Roswell Park Cancer InstituteClinicalTrials.gov Identifier:
NCT01522820
First received: January 25, 2012
Last updated: March 5, 2013
Drug: sirolimus
Other: laboratory biomarker analysis
Biological: DEC-205-NY-ESO-1 fusion protein vaccine
Last verified: March 2013 Adult Anaplastic Astrocytoma
Adult Anaplastic Oligodendroglioma
Adult Giant Cell Glioblastoma
Adult Glioblastoma
Adult Gliosarcoma
Adult Mixed Glioma
Adult Primary Hepatocellular Carcinoma
Chondrosarcoma
Clear Cell Sarcoma of the Kidney
Conjunctival Kaposi Sarcoma
Estrogen Receptor-negative Breast Cancer
Estrogen Receptor-positive Breast Cancer
Hormone-resistant Prostate Cancer
Limited Stage Small Cell Lung Cancer
Localized Resectable Adult Primary Liver Cancer
Male Breast Cancer
Mast Cell Sarcoma
Ovarian Sarcoma
Recurrent Adult Brain Tumor
Recurrent Adult Primary Liver Cancer
Recurrent Adult Soft Tissue Sarcoma
Recurrent Bladder Cancer
Recurrent Breast Cancer
Recurrent Colon Cancer
Recurrent Esophageal Cancer
Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Recurrent Gastric Cancer
Recurrent Kaposi Sarcoma
Recurrent Melanoma
Recurrent Non-small Cell Lung Cancer
Recurrent Osteosarcoma
Recurrent Ovarian Epithelial Cancer
Recurrent Ovarian Germ Cell Tumor
Recurrent Prostate Cancer
Recurrent Rectal Cancer
Recurrent Renal Cell Cancer
Recurrent Small Cell Lung Cancer
Recurrent Uterine Sarcoma
Small Intestine Leiomyosarcoma
Stage I Colon Cancer
Stage I Rectal Cancer
Stage I Uterine Sarcoma
Stage IA Breast Cancer
Stage IA Gastric Cancer
Stage IA Ovarian Epithelial Cancer
Stage IA Ovarian Germ Cell Tumor
Stage IB Breast Cancer
Stage IB Gastric Cancer
Stage IB Ovarian Epithelial Cancer
Stage IB Ovarian Germ Cell T -
Come on Share. You know me by now. I get carried away.
-
V, I will look at dndn. I think cldx is doing well because its breast cancer drug will start phase 3 later this year.
-
Celldex is the way to go.
-
Free, I admit Astex needs a kick start.
Sentiment: Strong Buy
-
-
Celldex's DEC-205 technology has countless applications. I'm surprised cldx is not at $20 today. Later this year cldx will be well over $20 imo.
Sentiment: Strong Buy
-
While you still can.
-
I assume we will hear something new at this big conference.
13-16 June 2013
European Hematology Association (EHA)
Stockholm, Sweden
presentingSentiment: Strong Buy
-
Because we are getting closer to news.
Sentiment: Strong Buy
-
Bump.....
- Reply to
Astex Pharmaceuticals Has a Catalyst-Driven Year Ahead (Part IV)
by abby_normal_2009 •Jun 9, 2013 3:05 PMWatch for late day buying.
Sentiment: Strong Buy